Therapeutic disruption of RAD52–ssDNA complexation via novel drug-like inhibitors is a research paper published in NAR Cancer (2023). On theSindex it has a DataRank of 0. It has been cited 13 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Institutes of Health
Grant: R01 CA232425
National Institutes of Health
Grant: R01 GM09737
National Institutes of Health
Grant: R01 GM138471
NIH-sponsored Predoctoral Training Program in Biotechnology
Grant: T32 GM008365
Free Radicals and Radiation Biology
Grant: T32 CA078586
NCI NIH HHS
Grant: P30 CA086862
National Institutes of Health
Grant: 3T32CA078586-05S1
TRAINING PROGRAM IN FREE RADICAL AND RADIATION BIOLOGY
National Institutes of Health
Grant: 2R01CA232425-06A1
The Role of Human RAD52 Protein in Genome Stability
National Institutes of Health
Grant: 5T32GM008365-20
Predoctoral Training Program in Biotechnology
National Institutes of Health
Grant: 5R01GM138471-03
Dialing down caspase-7 through allosteric control: An integrated approach
University of Iowa Center for Biocatalysis and Bioprocessing
FWCI
1.29
Citation Percentile
0.8%
Citation Trend
Fields of Study
Keywords
Sustainable Development Goals